Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system

Greiner RA, Braathen LR

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1684/ejd.2009.0725

Indexing Status
Subject indexing assigned by NLM

MeSH
Biological Products /economics /therapeutic use; Cost-Benefit Analysis; Delivery of Health Care; Humans; Psoriasis /drug therapy; Switzerland

AccessionNumber
22009103591

Date bibliographic record published
10/03/2010